LDE Stock Chart & Stats
€3.80
€0.04(1.08%)
At close: 4:00 PM EDT
€3.80
€0.04(1.08%)
Day’s Range― - ―
52-Week Range€3.12 - €7.30
Previous CloseN/A
Volume0.00
Average Volume (3M)61.00
Market Cap
€143.16M
Enterprise Value€386.59
Total Cash (Recent Filing)€17.47M
Total Debt (Recent Filing)€142.61M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding37,853,060
10 Day Avg. Volume0
30 Day Avg. Volume61
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.38Price Target Upside41.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.92
Revenue Forecast (FY)€105.25M
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionThe agreement expands Lifecore’s future commercial pipeline and adds another late-stage program to its platform. Although revenue is not expected until 2028, a larger pipeline can support multi-year growth and improve capacity utilization if technical transfer and production milestones are achieved.
Specialized CDMO ExpertiseLifecore operates in a specialized injectable CDMO niche spanning development and sterile fill-finish work. This technical scope can strengthen customer retention and create opportunities to support products from development through commercial manufacturing, deepening its role in client programs.
Improved Cash GenerationPositive operating and free cash flow in 2026 marks a meaningful improvement from prior periods and provides some internal funding for operations. If sustained, this improvement could reduce reliance on external financing and support investment in the company’s expanding commercial pipeline.
Bears Say
Highly Leveraged Balance SheetHigh debt combined with negative equity materially limits financial flexibility and raises refinancing and solvency risk. This capital structure can constrain investment in growth, increase sensitivity to operating setbacks, and leave fewer resources available to absorb weaker customer volumes or delays.
Persistent Losses And Flat RevenueLifecore has not yet converted its CDMO activity into consistent profitability: revenue remains broadly stagnant while operating and net losses persist. Continued earnings weakness could restrict internally funded growth and make the company more dependent on successful pipeline execution and financing access.
Uneven Cash Flow QualityThe latest cash-flow improvement is not yet a durable trend because free cash flow declined sharply year over year and operating cash flow was historically inconsistent. Such volatility makes planning and debt service more difficult, while weakening confidence that operations can reliably fund future needs.
Lifecore Biomedical News
LDE FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was €3.12 and its highest was €7.30 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is €143.16M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is May 12, 2027 which is in 245 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Aug 05, 2026. The company reported -€0.163 earnings per share for the quarter, beating the consensus estimate of -€0.191 by €0.028.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Undervalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,853,060 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -€0.163 in its last earnings report, beating expectations of -€0.191. Following the earnings report the stock price went up 1.63%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in DE:LDE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LDE Company Deck
LDE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.View all DE:LDE earnings summariesLDE Stock 12 Month Forecast
Average Price Target
€5.38
▲(41.63% Upside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―